| NIA‐AA research framework: toward a biological definition of Alzheimer's disease CR Jack Jr, DA Bennett, K Blennow, MC Carrillo, B Dunn, SB Haeberlein, ... Alzheimer's & dementia 14 (4), 535-562, 2018 | 8628 | 2018 |
| Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment B Winblad, K Palmer, M Kivipelto, V Jelic, L Fratiglioni, LO Wahlund, ... Journal of internal medicine 256 (3), 240-246, 2004 | 5997 | 2004 |
| Alzheimer's disease K Blennow, MJ de Leon, H Zetterberg The Lancet 368 (9533), 387-403, 2006 | 4833 | 2006 |
| Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria B Dubois, HH Feldman, C Jacova, H Hampel, JL Molinuevo, K Blennow, ... The Lancet Neurology 13 (6), 614-629, 2014 | 3856 | 2014 |
| Alzheimer's disease P Scheltens, K Blennow, MMB Breteler, B De Strooper, GB Frisoni, ... The Lancet 388 (10043), 505-517, 2016 | 3571 | 2016 |
| Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects LM Shaw, H Vanderstichele, M Knapik‐Czajka, CM Clark, PS Aisen, ... Annals of neurology 65 (4), 403-413, 2009 | 2349 | 2009 |
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease K Blennow, H Hampel, M Weiner, H Zetterberg Nature Reviews Neurology 6 (3), 131-144, 2010 | 2253 | 2010 |
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease S Salloway, R Sperling, NC Fox, K Blennow, W Klunk, M Raskind, ... New England Journal of Medicine 370 (4), 322-333, 2014 | 2209 | 2014 |
| Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study O Hansson, H Zetterberg, P Buchhave, E Londos, K Blennow, L Minthon The Lancet Neurology 5 (3), 228-234, 2006 | 2183 | 2006 |
| CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis B Olsson, R Lautner, U Andreasson, A Öhrfelt, E Portelius, M Bjerke, ... The Lancet Neurology 15 (7), 673-684, 2016 | 2141 | 2016 |
| Alzheimer's disease CL Masters, R Bateman, K Blennow, CC Rowe, RA Sperling, ... Nature reviews disease primers 1 (1), 1-18, 2015 | 2011 | 2015 |
| Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria B Dubois, H Hampel, HH Feldman, P Scheltens, P Aisen, S Andrieu, ... Alzheimer's & Dementia 12 (3), 292-323, 2016 | 1997 | 2016 |
| Gut microbiome alterations in Alzheimer’s disease NM Vogt, RL Kerby, KA Dill-McFarland, SJ Harding, AP Merluzzi, ... Scientific reports 7 (1), 13537, 2017 | 1914 | 2017 |
| A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers CR Jack Jr, DA Bennett, K Blennow, MC Carrillo, HH Feldman, GB Frisoni, ... Neurology 87 (5), 539-547, 2016 | 1795 | 2016 |
| Neurofilaments as biomarkers in neurological disorders M Khalil, CE Teunissen, M Otto, F Piehl, MP Sormani, T Gattringer, ... Nature Reviews Neurology 14 (10), 577-589, 2018 | 1755 | 2018 |
| CSF markers for incipient Alzheimer's disease K Blennow, H Hampel The Lancet Neurology 2 (10), 605-613, 2003 | 1704 | 2003 |
| Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms, P Scheltens, ... Jama 313 (19), 1924-1938, 2015 | 1673 | 2015 |
| Clearance systems in the brain—implications for Alzheimer disease JM Tarasoff-Conway, RO Carare, RS Osorio, L Glodzik, T Butler, ... Nature reviews neurology 11 (8), 457-470, 2015 | 1633 | 2015 |
| CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment N Mattsson, H Zetterberg, O Hansson, N Andreasen, L Parnetti, ... Jama 302 (4), 385-393, 2009 | 1465 | 2009 |
| Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins S Ray, M Britschgi, C Herbert, Y Takeda-Uchimura, A Boxer, K Blennow, ... Nature medicine 13 (11), 1359-1362, 2007 | 1332 | 2007 |
